Nyheter/rapporter

Senaste pressmeddelanden och rapporter för bevakat bolag.

Datum Källa Rubrik Typ Alternativ
2024-02-22 Vivesto Bokslutskommuniké för räkenskapsåret 1 januari – 31 december 2023 Rapporter Ladda ner | Visa Stäng
2024-01-30 Vivesto Vivestos internationella patentansökan för XR-18 får positivt besked Pressreleaser Ladda ner | Visa Stäng
2024-01-30 Vivesto Vivesto's international patent application for XR-18 receives positive decision Pressreleaser Ladda ner | Visa Stäng
2023-12-28 Vivesto Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment Pressreleaser Ladda ner | Visa Stäng
2023-12-28 Vivesto Vivestos amerikanska kliniska studie med Paccal Vet får godkänt att starta patientrekrytering Pressreleaser Ladda ner | Visa Stäng
2023-12-22 Vivesto Vivestos Paccal Vet beviljas MUMS-klassificering av FDA Pressreleaser Ladda ner | Visa Stäng
2023-12-22 Vivesto Vivesto’s Paccal Vet granted FDA MUMS designation Pressreleaser Ladda ner | Visa Stäng
2023-12-22 Vivesto Vivesto gör nedskrivning av tillgångar efter tillbakadragande av de europeiska marknadsföringstillstånden för Apealea Pressreleaser Ladda ner | Visa Stäng
2023-12-22 Vivesto Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea Pressreleaser Ladda ner | Visa Stäng
2023-12-19 Vivesto Vivesto reports positive preclinical data supporting continued development of Cantrixil Pressreleaser Ladda ner | Visa Stäng
2023-12-19 Vivesto Vivesto rapporterar positiva prekliniska data som stödjer fortsatt utveckling av Cantrixil Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Vivesto Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Vivesto Valberedning utsedd inför Vivestos årsstämma 2024 Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Vivesto Vivesto och Elevar tecknar avtal för att avsluta partnerskap rörande Apealea® Pressreleaser Ladda ner | Visa Stäng
2023-11-23 Vivesto Vivesto and Elevar sign agreement ending Apealea® partnership Pressreleaser Ladda ner | Visa Stäng
2023-11-17 Penser Access Penser Access: Intervju med Vivesto - Erik Penser Bank - 17 november 2023 Pressreleaser Visa Stäng
2023-11-16 Vivesto Interim report for the period January 1, 2023 – September 30, 2023 Rapporter Ladda ner | Visa Stäng
2023-11-16 Vivesto Delårsrapport för perioden 1 januari – 30 september 2023 Rapporter Ladda ner | Visa Stäng
2023-10-26 Penser Access Penser Access: Intervju med Vivesto - Erik Penser Bank - 26 oktober 2023 Pressreleaser Visa Stäng
2023-10-25 Vivesto Vivesto focuses its project portfolio and introduces cost-saving measures Pressreleaser Ladda ner | Visa Stäng
2023-10-25 Vivesto Vivesto fokuserar projektportföljen och inför kostnadsbesparande åtgärder Pressreleaser Ladda ner | Visa Stäng
2023-09-15 Vivesto Avnotering av Vivestos aktier från Frankfurt Stock Exchange per den 15 september 2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-15 Vivesto Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023 Pressreleaser Ladda ner | Visa Stäng
2023-08-24 Vivesto Delårsrapport för perioden 1 januari – 30 juni 2023 Rapporter Ladda ner | Visa Stäng
2023-08-24 Vivesto Interim report for the period January 1, 2023 – June 30, 2023 Rapporter Ladda ner | Visa Stäng
2023-08-04 Vivesto Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study Pressreleaser Ladda ner | Visa Stäng
2023-08-04 Vivesto Vivesto meddelar att rekryteringen av patienter i den prövarinitierade fas 1b-studien med Docetaxel micellar avslutas i förtid Pressreleaser Ladda ner | Visa Stäng
2023-06-16 Vivesto Vivesto har haft positivt pre-submission möte med FDA om Paccal Vet Pressreleaser Ladda ner | Visa Stäng
2023-06-16 Vivesto Vivesto announces positive Paccal Vet FDA pre-submission meeting Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Vivesto Kommuniké från årsstämma i Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Vivesto Report from Annual General Meeting in Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-05-25 Vivesto Delårsrapport för perioden januari – mars 2023 Rapporter Ladda ner | Visa Stäng
2023-05-25 Vivesto Interim report for the period January 2023 – March 2023 Rapporter Ladda ner | Visa Stäng
2023-04-25 Vivesto Kallelse till årsstämma i Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Vivesto Notice of Annual General Meeting in Vivesto AB Pressreleaser Ladda ner | Visa Stäng
2023-04-25 Vivesto Vivesto publicerar årsredovisning för 2022 Rapporter Ladda ner | Visa Stäng
2023-04-25 Vivesto Vivesto publishes Annual Report for 2022 Rapporter Ladda ner | Visa Stäng
2023-03-24 Vivesto Vivesto och Elevar avser överlåta Elevars rättigheter och skyldigheter för Apealea till tredje part Pressreleaser Ladda ner | Visa Stäng
2023-03-24 Vivesto Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 24 Mar 2023 | Vivesto

Vivesto and Elevar seek to transfer Elevar’s Apealea rights and obligations to a third party

Vivesto AB, an oncology-focused R&D company, has been informed that Elevar Therapeutics Inc., which holds the rights to commercialize Vivesto’s anticancer product Apealea, intends to transfer its rights and obligations to a third party. A transfer of rights and obligations would require Vivesto’s consent, and no such consent has been given yet.

A transfer may be in Vivesto’s interest in terms of Apealea’s commercialization and development progress. Considering the current uncertainty regarding the launch activities of Apealea, Vivesto will write down balance sheet items preliminary amounting in total to MSEK 190. The impairment charge and write down have no cash flow impact, nor any other material impact on the company’s financial position.

A new partner could reignite the Apealea project,” said Erik Kinnman, CEO of Vivesto. “We will together with Elevar vigorously explore any opportunities emerging in this new situation, and in parallel seek a partner for China, which we see as a considerable and prioritized market opportunity.

In 2020, Vivesto and Elevar entered into a global strategic partnership for the commercialization of Apealea, granting Elevar an exclusive right to commercialize Apealea. Under the arrangement Elevar has the right to sub-license Apealea to other strategic partners, and such sub-licenses have been granted to Inceptua SA in Europe, Taiba Middle East FZ LLC in certain countries throughout the MENA region, and to Tanner Pharma Group Inc. in South America.

Elevar has informed Vivesto that the company is discontinuing its efforts to develop and commercialize Apealea and instead seeks to transfer its rights and obligations Vivesto’s understanding is that launch activities and sales in Europe are developing slower than expected, partially dependent upon Elevar only being able to provide Inceptua with limited Apealea supply.

Vivesto’s view is that a transfer may be in Vivesto’s interest. Based on this, Vivesto has informed Elevar that Vivesto is open to evaluate a request by Elevar to transfer rights and obligations and Vivesto is ready to negotiate in good faith the terms for such transfer.

In light of the increased uncertainty relating to the commercialization of Apealea, Vivesto has made an impairment test of the book values of the project, which as of December 31, 2022 totalled MSEK 229, and decided to write down some of the capitalized development costs. The amount of impairment is preliminary calculated to MSEK 180, which will be recorded as an expense. In addition to this the inventory and other equipment will be written down with MSEK 10. The impairment charge and write down will be included in the annual report of 2022, which will be released in April, 2023. The impairment charge and write down have no cash flow impact, nor any other material impact on the company’s financial position.

For further information:

Erik Kinnman, Chief Executive Officer

Phone: +46 18-50 54 40

E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of clinical-stage projects targeting advanced cancer. Apealea® (paclitaxel micellar) is made available to patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in long-developed ovarian cancer, and Docetaxel micellar being developed for metastatic prostate cancer. Vivesto’s proprietary and patented technology platform is developed to improve the water solubility, efficacy and safety of pharmaceuticals. The company’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about Vivesto.

This information is information that Vivesto AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on [•] March 2023 at xx:xx CET.

2023-03-20 Vivesto Vivesto initiates clinical development of Paccal Vet in veterinary oncology Pressreleaser Ladda ner | Visa Stäng
2023-03-20 Vivesto Vivesto inleder klinisk utveckling av Paccal Vet inom veterinäronkologi Pressreleaser Ladda ner | Visa Stäng
2023-02-27 Penser Access Penser Access: Vi ser fram emot ökad tydlighet - Vivesto Pressreleaser Visa Stäng

Kommande händelser

23 May 2024 | Årsstämma 2023
23 May 2024 | Kvartalsrapport 2024-Q1
22 Aug 2024 | Kvartalsrapport 2024-Q2
21 Nov 2024 | Kvartalsrapport 2024-Q3
20 Feb 2025 | Bokslutskommuniké 2024